A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors
Loading...
Date
Authors
Kalbakis, K.
Pappas, P.
Kouroussis, C.
Vamvakas, L.
Kalykaki, A.
Vardakis, N.
Nikolaidou, M.
Marselos, M.
Georgoulias, V.
Mavroudis, D.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Cancer Chemother Pharmacol
Book name
Book series
Book edition
Alternative title / Subtitle
Description
PURPOSE: To evaluate the maximum tolerated doses (MTD) and the dose-limiting toxicities (DLT) of the combination of pegylated liposomal doxorubicin (PEG-LD), paclitaxel and oxaliplatin (L-OHP) administered every 2 weeks in patients with advanced solid tumors. METHODS: Thirty-nine pretreated patients with advanced solid tumors received escalated doses of PEG-LD (10-16 mg/m(2)), paclitaxel (100-120 mg/m(2)) and L-OHP (50-70 mg/m(2)) every 2 weeks. As one cycle of treatment was considered the administration of both drugs on days 1 and 15 of a 4-week cycle. RESULTS: The MTDs were PEG-LD 14 mg/m(2), paclitaxel 120 mg/m(2) and L-OHP 70 mg/m(2). Neutropenia was the DLT in all but one case with only one episode of febrile neutropenia and no toxic deaths. Four (4%) and 13 (12%) cycles were complicated by grades 4 and 3 neutropenia, respectively. Grades 2-3 fatigue and neurotoxicity occurred in 13 and 12% of cycles, respectively. Responses were observed in patients with breast, endometrial and ovarian carcinomas. CONCLUSIONS: This is a quite well-tolerated regimen which merits further evaluation in phase II studies.
Description
Keywords
Adult, Aged, *Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse, effects/pharmacokinetics/therapeutic use, Disease-Free Survival, Dose-Response Relationship, Drug, Doxorubicin/administration & dosage/adverse effects/pharmacokinetics/therapeutic, use, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Invasiveness, Neoplasms/*drug therapy/pathology, Organoplatinum Compounds/administration & dosage/adverse, effects/pharmacokinetics/therapeutic use, Paclitaxel/administration & dosage/adverse effects/pharmacokinetics/therapeutic, use
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/17960381
http://www.springerlink.com/content/7447319178378k8w/fulltext.pdf
http://www.springerlink.com/content/7447319178378k8w/fulltext.pdf
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής